Medarex Inc. usually receives fees from its partners for use of its human antibody-generating technology. But in a deal announced last week, MEDX is essentially paying Eos Biotechnology Inc. to use its HuMAb-Mouse technology.

What is different in this case, said Eos President and CEO David Martin, is that MEDX gets to build a pipeline without